2026 Q2 - tulosraportti
Vain PDF
44 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 552 | - | - | ||
| 1 094 | - | - | ||
| 249 | - | - | ||
| 358 | - | - | ||
| 188 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 3.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 18.2. | ||
2025 Q3 - tulosraportti 30.10.2025 | ||
2025 Q2 - tulosraportti 20.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·26.9.If you look at what has actually happened during 2026, quite a lot has moved the company forward: • ADVANCE – positive clinical effects, incl. significant CRP and SDAI improvement. The data from ADVANCE is really strong and furthermore not immunosuppressive. Safety is magically good and exactly what the FDA is looking at in Q4. • New post-hoc analysis strengthens EXPAND/ADVANCE and supports a phase 3 program. FDA discussion planned for Q4 as mentioned. • WHO/Lancet Microbe has identified resomelagon as one of only six dengue candidates with sufficient evidence for continued clinical development! And the only host-directed therapy in the selection. • Brazil: Term sheet with Hipolabor for the first commercial agreement within dengue. According to the latest presentation this week, the hope is that the ink is on the paper in just over 4 weeks. • US patent secures exclusivity for resomelagon until 2044. • Resomelagon is being developed in parallel within RA, dengue, respiratory infections, PMR, kidney disease and OA. • BIO and other partner/investor meetings have, according to the company, shown an increasing interest after ADVANCE while SEVERAL Big Pharma companies have a new narrative on social media among other things but also their own articles. Something Synact is absolute foremost within. Despite all this, the stock trades around 17-18 kr? Incredible actually. The interesting thing is that we are also facing several potentially major value drivers: FDA dialogue, dengue data and commercial Brazil agreement, but also of course a deal of the larger sort. Something I think definitely is in the cards as we speak. Not just Jeppe but both Mads and Thomas Jonassen emphasize the increased interest around Resomelagon. Not taking control of this product will lead to a lot of value loss for a larger company - because Resomelagon is a first in line treatment that "steals" market share from second and third line treatment. It is not only the most knowledgeable invested who have realized that this form of treatment is difficult to understand and get into. It is something management has also understood and spent more time educating the market on, but also larger companies within. Said many times before, but risk vs reward is incredible right now when Synact is further along than ever.
"Flere big pharma har ett nytt narrariv" - kan du gi noen eksempler på dette? Jeg er enig med at Aksjen er fryktelig undervurdert.
·11.9.Check this about Dengue: Resomelagon selected by WHO as one of six! https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(26)00106-0/fulltext
4.9.Jeppe and Thomas could've sold shares in January at market price 21-24, but didn't. The holding company is responsible for its' own taxation, maybe there are other assets inside, but I'm guessing Synact is the primary reason for the amount needed. If they sold the shares based on insider info, they'd be in big trouble. I'm not losing any sleep over this. (I just had to join the forum to put my two cents in)
It's probably more that one chooses to sell shares! Doesn't feel like there's anything big in the pipeline right now👀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
Vain PDF
44 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·26.9.If you look at what has actually happened during 2026, quite a lot has moved the company forward: • ADVANCE – positive clinical effects, incl. significant CRP and SDAI improvement. The data from ADVANCE is really strong and furthermore not immunosuppressive. Safety is magically good and exactly what the FDA is looking at in Q4. • New post-hoc analysis strengthens EXPAND/ADVANCE and supports a phase 3 program. FDA discussion planned for Q4 as mentioned. • WHO/Lancet Microbe has identified resomelagon as one of only six dengue candidates with sufficient evidence for continued clinical development! And the only host-directed therapy in the selection. • Brazil: Term sheet with Hipolabor for the first commercial agreement within dengue. According to the latest presentation this week, the hope is that the ink is on the paper in just over 4 weeks. • US patent secures exclusivity for resomelagon until 2044. • Resomelagon is being developed in parallel within RA, dengue, respiratory infections, PMR, kidney disease and OA. • BIO and other partner/investor meetings have, according to the company, shown an increasing interest after ADVANCE while SEVERAL Big Pharma companies have a new narrative on social media among other things but also their own articles. Something Synact is absolute foremost within. Despite all this, the stock trades around 17-18 kr? Incredible actually. The interesting thing is that we are also facing several potentially major value drivers: FDA dialogue, dengue data and commercial Brazil agreement, but also of course a deal of the larger sort. Something I think definitely is in the cards as we speak. Not just Jeppe but both Mads and Thomas Jonassen emphasize the increased interest around Resomelagon. Not taking control of this product will lead to a lot of value loss for a larger company - because Resomelagon is a first in line treatment that "steals" market share from second and third line treatment. It is not only the most knowledgeable invested who have realized that this form of treatment is difficult to understand and get into. It is something management has also understood and spent more time educating the market on, but also larger companies within. Said many times before, but risk vs reward is incredible right now when Synact is further along than ever."Flere big pharma har ett nytt narrariv" - kan du gi noen eksempler på dette? Jeg er enig med at Aksjen er fryktelig undervurdert.
- ·11.9.Check this about Dengue: Resomelagon selected by WHO as one of six! https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(26)00106-0/fulltext
- 4.9.Jeppe and Thomas could've sold shares in January at market price 21-24, but didn't. The holding company is responsible for its' own taxation, maybe there are other assets inside, but I'm guessing Synact is the primary reason for the amount needed. If they sold the shares based on insider info, they'd be in big trouble. I'm not losing any sleep over this. (I just had to join the forum to put my two cents in)It's probably more that one chooses to sell shares! Doesn't feel like there's anything big in the pipeline right now👀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 552 | - | - | ||
| 1 094 | - | - | ||
| 249 | - | - | ||
| 358 | - | - | ||
| 188 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 3.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 18.2. | ||
2025 Q3 - tulosraportti 30.10.2025 | ||
2025 Q2 - tulosraportti 20.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
Vain PDF
44 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 3.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 18.2. | ||
2025 Q3 - tulosraportti 30.10.2025 | ||
2025 Q2 - tulosraportti 20.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·26.9.If you look at what has actually happened during 2026, quite a lot has moved the company forward: • ADVANCE – positive clinical effects, incl. significant CRP and SDAI improvement. The data from ADVANCE is really strong and furthermore not immunosuppressive. Safety is magically good and exactly what the FDA is looking at in Q4. • New post-hoc analysis strengthens EXPAND/ADVANCE and supports a phase 3 program. FDA discussion planned for Q4 as mentioned. • WHO/Lancet Microbe has identified resomelagon as one of only six dengue candidates with sufficient evidence for continued clinical development! And the only host-directed therapy in the selection. • Brazil: Term sheet with Hipolabor for the first commercial agreement within dengue. According to the latest presentation this week, the hope is that the ink is on the paper in just over 4 weeks. • US patent secures exclusivity for resomelagon until 2044. • Resomelagon is being developed in parallel within RA, dengue, respiratory infections, PMR, kidney disease and OA. • BIO and other partner/investor meetings have, according to the company, shown an increasing interest after ADVANCE while SEVERAL Big Pharma companies have a new narrative on social media among other things but also their own articles. Something Synact is absolute foremost within. Despite all this, the stock trades around 17-18 kr? Incredible actually. The interesting thing is that we are also facing several potentially major value drivers: FDA dialogue, dengue data and commercial Brazil agreement, but also of course a deal of the larger sort. Something I think definitely is in the cards as we speak. Not just Jeppe but both Mads and Thomas Jonassen emphasize the increased interest around Resomelagon. Not taking control of this product will lead to a lot of value loss for a larger company - because Resomelagon is a first in line treatment that "steals" market share from second and third line treatment. It is not only the most knowledgeable invested who have realized that this form of treatment is difficult to understand and get into. It is something management has also understood and spent more time educating the market on, but also larger companies within. Said many times before, but risk vs reward is incredible right now when Synact is further along than ever."Flere big pharma har ett nytt narrariv" - kan du gi noen eksempler på dette? Jeg er enig med at Aksjen er fryktelig undervurdert.
- ·11.9.Check this about Dengue: Resomelagon selected by WHO as one of six! https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(26)00106-0/fulltext
- 4.9.Jeppe and Thomas could've sold shares in January at market price 21-24, but didn't. The holding company is responsible for its' own taxation, maybe there are other assets inside, but I'm guessing Synact is the primary reason for the amount needed. If they sold the shares based on insider info, they'd be in big trouble. I'm not losing any sleep over this. (I just had to join the forum to put my two cents in)It's probably more that one chooses to sell shares! Doesn't feel like there's anything big in the pipeline right now👀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 552 | - | - | ||
| 1 094 | - | - | ||
| 249 | - | - | ||
| 358 | - | - | ||
| 188 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt